### Name of Journal: *World Journal of Gastroenterology*

### ESPS Manuscript NO: 30101

### Manuscript Type: ORIGINAL ARTICLES

### *Observational Study*

### Serum omentin and vaspin levels in cirrhotic patients with and without portal vein thrombosis

Kukla M *et al.* Omentin and vaspin in liver cirrhosis.

Michał Kukla, Marek Waluga, Michał Żorniak, Agnieszka Berdowska, Piotr Wosiewicz, Tomasz Sawczyn, Rafał J Bułdak, Marek Ochman, Katarzyna Ziora, Tadeusz Krzemiński, Marek Hartleb

**Michał Kukla, Marek Waluga, Michał Żorniak, Piotr Wosiewicz, Marek Hartleb,** Department of Gastroenterology and Hepatology, Medical University of Silesia in Katowice, 40-752 Katowice, Poland

**Agnieszka Berdowska,** Department of Microbiology and Biotechnology, Jan Długosz University, 42-200 Częstochowa, Poland

**Tomasz Sawczyn,** Department of Physiology, Medical University of Silesia in Katowice, 41-800 Zabrze, Poland

**Rafał J Bułdak,** Department of Biochemistry in Zabrze, Medical University of Silesia in Katowice, 41-800 Zabrze, Poland

**Marek Ochman,** Department of Cardiac Surgery and Transplantation, Silesian Center for Heart Diseases, 41-800 Zabrze, Poland

**Katarzyna Ziora**, Department of Pediatrics, Medical University of Silesia in Katowice, 41-800 Zabrze, Poland

**Tadeusz Krzemiński,** Department of Pharmacology, Medical University of Silesia in Katowice, 41-800 Zabrze, Poland

**Author contributions:** Kukla M contributed to study design, data collection, data interpretation, manuscript preparation, literature search, funds collection, critical revisions related to important intellectual content of the manuscript; Waluga M contributed to data collection, data interpretation, manuscript preparation, literature search, funds collection, critical revisions related to important intellectual content of the manuscript; Żorniak M contributed to data collection, manuscript preparation; Berdowska A contributed to statistical analysis; Wosiewicz P contributed to literature search, data collection; Sawczyn T, Bułdak RJ contributed to data interpretation, data collection; Ochman M contributed to manuscript preparation, funds collection; Ziora K contributed to data interpretation, literature search; Krzemiński T contributed to data collection; Hartleb M contributed to data interpretation, manuscript preparation, literature search, funds collection, critical revisions related to important intellectual content of the manuscript

**Supported by** Medical University of Silesia– Contract, No. KNW1-090/N/6/0.

**Institutional review board statement:** The study was reviewed and approved by Department of Science of Medical University of Silesia in Katowice.

**Informed consent statement:** All study participants provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** There are no conflicts of interest to report.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to: Michał Kukla, MD, PhD,** Medical University of Silesia, Department of Gastroenterology and Hepatology, Medyków14 street, 40-752 Katowice, Poland. [kuklamich@poczta.onet.pl](mailto:kuklamich@poczta.onet.pl)

**Telephone:** +48-327894401

**Fax:** +48-327894402

**Received**: September 11, 2016

**Peer-review started:** September 12, 2016

**First decision:** November 21, 2016

**Revised:** February 24, 2017

**Accepted:** March 15, 2017

**Article in press:**

**Published online:**

Abstract

***AIM***

To investigate serum omentin and vaspin levels in cirrhotic patients; and to assess the relationship of these levels with hemostatic parameters, metabolic abnormalities, cirrhosis severity and etiology

***MOTHODS***

Fifty-one cirrhotic patients (17 with portal vein thrombosis) were analyzed. Serum omentin and vaspin levels were measured with commercially available direct enzyme-linked immunosorbent assays (ELISAs). To assess platelet activity, the following tests were performed using a MULTIPLATE®PLATELET FUNCTION ANALYZER: (1) an ADP-induced platelet activation test; (2) a cyclooxygenase dependent aggregation test (ASPI test); (3) a von Willebrand factor and glycoprotein Ib-dependent aggregation (using ristocetin) test (RISTO test); and (4) a test for thrombin receptor-activating peptide-6 induced activation of the thrombin receptor, which is sensitive to IIb/IIIa receptor antagonists.

***RESULTS***

Omentin, but not vaspin, serum concentrations were significantly decreased in patients with portal vein thrombosis (PVT) (*P =* 0.01). Prothrombin levels were significantly increased in patients with PVT (*P =* 0.01). The thrombin receptor activating peptide (TRAP) test results were significantly lower in the PVT group (*P =* 0.003). No significant differences in adipokines serum levels were found regarding the etiology or severity of liver cirrhosis assessed according to the Child-Pugh or Model of End-Stage Liver Disease (MELD) scores. There was a significant increase in the TRAP (*P =* 0.03), ASPI (*P =* 0.001) and RISTO high-test (*P =* 0.02) results in patients with lower MELD scores. Serum omentin and vaspin levels were significantly down-regulated in patients without insulin resistance (*P =* 0.03; *P =* 0.02, respectively). A positive relationship between omentin and vaspin levels were found both when all of the patients were analyzed (*r =* 0.41; *P =* 0.01) and among those with PVT (*r =* 0.94; *P <* 0.001).

***CONCLUSION***

Serum omentin levels are increased in patients with PVT. Cirrhosis origin and grade do not affect omentin and vaspin levels. The analyzed adipokines do not influence platelet activity.

**Key words:** Omentin; Vaspin; Cirrhosis; Adipokine; Portal vein thrombosis; Portal hypertension

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Accumulating data suggest that obesity and insulin resistance are related to a more rapid progression of chronic liver diseases, the development of cirrhosis and its complications. Some adipokines have been suggested to contribute to the complicated pathophysiology of hepatic injury and repair. Ongoing research has revealed alterations in the levels and expression of various adipokines in cirrhosis. Portal vein thrombosis (PVT) has been considered to be a complication of more advanced liver cirrhosis. The data regarding novel adipokines in liver cirrhosis is scare and ambiguous. The current study evaluated the serum concentrations of omentin and vaspin in patients with liver cirrhosis of different origins and stages with and without PVT. The relationships of these measures with disease severity and etiology, platelet activity, hemostatic parameters and potential complications were also assessed. The study included 51 patients with cirrhosis of different etiologies (alcohol in 30 patients, hepatitis C virus infection in 15, autoimmune hepatitis in 6). Seventeen these patients manifested portal vein thrombosis confirmed by contrast-enhanced computed tomography.

KuklaM, Waluga M, Żorniak M, Berdowska A, Wosiewicz P, Sawczyn T, Bułdak RJ, Ochman M, Ziora K, Krzemiński T, Hartleb M. Serum omentin and vaspin levels in cirrhotic patients with and without portal vein thrombosis. *World J Gastroenterol* 2017; In press

INTRODUCTION

Liver cirrhosis is associated with progressive liver impairment, leading to the development of numerous complications, including portal hypertension and portal vein thrombosis (PVT)[1].PVT is generally recognized as rare in the general population, being primarily a consequence of myeloproliferative diseases, genetic or acquired thrombophilia or inflammation in the abdominal cavity[2].However,PVT is a relatively common complication of liver cirrhosis, with an estimated frequency of 5%–28%[3,4].Excessive hepatic deposition of fibrotic tissue contributes to intra-hepatic resistance, an up-regulation of portal blood pressure and a reduction in portal blood flow into the liver[5].

Adipokines are polypeptide hormones that are primarily produced by adipocytes. Apart from fat cells, adipose tissue is composed of stromal cells, including macrophages, fibroblasts and infiltrating monocytes, all of which may serve as an additional source of adipokines[6]. Accumulating data reveal disturbances in the secretion of some adipokines in chronic liver diseases (CLDs) and cirrhosis, leading to the complex pathophysiology of hepatic injury and healing[7]. Some adipokines are also recognized to be active as pro-fibrotic and pro-thrombotic agents. The best of these is known leptin, receptors for which have been identified in hepatic stellate cells (HSCs) and many types of vascular cells, including sinusoidal endothelial cells (SECs), macrophages (Kupffer cells) and platelets[8-10].Another adipokine, adiponectin, exerts opposite anti-fibrotic and anti-inflammatory effects[11].Novel adipokines and hepatokines were recently described, and their role in liver diseases are now being intensively investigated[7].

Omentin-1 (intelectin-1, also known as an active endothelial factor) is a newly identified adipokine that is highly and selectively expressed in visceral adipose tissue[12,13]. The data regarding hepatic omentin expression is equivocal. Our previous study confirmed omentin expression in the liver tissue from chronic hepatitis C (CHC) patients[14].However, an earlier study by Yang *et al*. found higher omentin expression in the stroma-vascular cells of omental fat and lower expression in the intestine and lung; no expression was observed in the liver, kidney and pancreas[15].Omentin has been suggested to be a “good adipokine” because its serum concentration were negatively associated with a multiplicity of metabolic risk factors in metabolic syndrome (MS)[16].A previous study by Pan *et al*. revealed significantly lower serum omentin levels in patients with diabetes mellitus (DM)[17].However, the role of omentin in CLD is unclear. A small number of studies have shown that omentin serum are levels increased in CHC, NAFLD and cirrhosis[14,18,19].

Vaspin (visceral adipose tissue-derived serine protease inhibitor) is a novel adipokine that was isolated from both the visceral and subcutaneous white adipose tissues of subjects with obesity and impaired glucose tolerance[20].Vaspin has also been confirmed to down-regulate the expression of profibrogenic and proinflammatory agents, such as leptin, tumor necrosis factor (TNF)-alpha and resistin[7].Some studies have indicated that the induction of vaspin mRNA expression in human adipose tissue might be a compensatory mechanism associated with obesity and increasing insulin resistance (IR)[7]. Serum levels of vaspin in CHC patients without fibrosis or with less advanced fibrosis were significantly lower than in healthy controls. However, in patients with bridging fibrosis or cirrhosis, the levels were almost as high as in the control group[21,22].In NAFLD patients, vaspin serum levels seemed to be higher in patients with definite NASH and more advanced fibrosis[23,24].

In light of the aforementioned studies, we decided to investigate serum concentrations of two novel adipokines, omentin and vaspin, in cirrhotic patients with and without PVT. These analyses were performed to assess their prothrombotic action. We then analyzed the association between the serum levels of these adipokines and hemostatic parameters, platelet counts and platelet-aggregation activity markers. We also elucidated the relationship between omentin and vaspin serum levels and cirrhosis severity, etiology and metabolic abnormalities.

MATERIALS AND METHODS

***Study population***

A total of 51 patients (16 females) with cirrhosis of different etiologies (alcohol in 30 patients (51%), hepatitis C virus (HCV) infection (genotype 1b) in 15 (29%), and autoimmune hepatitis in 6 (12%)) were enrolled. After meeting the qualification criteria, the presence of portal vein thrombosis in 17 was confirmed using contrast-enhanced computed tomography. Data on complications of the liver disease, present and past co-morbidities and current medication use were collected. Patients were excluded for the following reasons: infection with HCV genotypes other than 1b; hepatitis B virus infection; human immunodeficiency virus (HIV) co-infection; drug abuse; the presence of neoplastic, thyroid or psychiatric diseases; or renal or heart failure. Contrast-enhanced spiral computed-tomography was performed on each patient to confirm the presence of PVT. Computed tomography was independently evaluated by two experienced radiologists. The severity of cirrhosis was evaluated by the Model of End-Stage Liver Disease (MELD) and the Child-Pugh score. For further analysis, the patients were divided according to their Child-Pugh score (from A to C) or divided in two subgroups according to MELD scores > 18 and ≤ 18. This cut-off was determined based on studies that assessed MELD predictive values in patients with end-stage liver disease[25]. The baseline clinical and laboratory characteristics of the patients are presented in Table 1.

***Ethics statement***

The study protocol was approved by the Local Bioethical Committee of the Medical University of Silesia (Approval of Committee NoKNW/0022/KB1/45/II/15, Nov172015). All of the clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki. All of the study participants provided informed written consent prior to study enrollment.

***Biochemical and serological assays***

Biochemical parameters were measured using routine methods. The upper limit of ALT activity was set at 38 IU/L, that of AST at 40 IU/L and that of gamma-glutamyltransferase (GGT) activity at 50 IU/L. The upper total serum bilirubin concentration was set at 17 μmol/L. Insulin concentrations were measured with a DiaMetra Insulin EIA Kit, Cat. No DKO076 (DiaMetra, Italy). For IR estimation, the homeostatic model assessment (HOMA-IR) was calculated using the following formula: fasting insulin level (mUI/L) × fasting glucose level (mg/dl)/405. With respect to the HOMA-IR value, the patients were divided into two subgroups - below and equal or greater than 3.0. The cut-off was determined on the basis of reviewed recent literature[26].

The blood samples were drawn from the antebrachial vein after 16 h of fasting and were the centrifuged. The serum was frozen and stored for further analysis at a temperature of -70 °C. Commercially available direct enzyme-linked immunosorbent assays (ELISA) were used for measurement of the serum omentin and vaspin levels (BioVendor; Brno, Czech Republic).

Blood platelets play a pivotal role in physiological hemostasis but also in the development of thrombosis. In addition to increased circulating prothrombotic agents, such as von Willebrand factor (vWf), changes in platelet biology and function may underlie up-regulated thrombotic risk in cirrhosis. These changes include an increase in mean platelet volume, enhanced platelet aggregatory response to agonists and a resistance to the anti-aggregatory effects of nitric oxide and prostacyclin I2.

Platelet function testing is used to analyze inherited and acquired platelet function disorders. In our study, platelet activity was examined with the MULTIPLATE®PLATELET FUNCTION ANALYZER (Roche; Basel, Switzerland) using multiple electrode aggregometry (MEA). The Multiplate® analyzer is an easy-to-use instrument that standardizes platelet function testing in small quantities of whole blood.

Platelet activity was examined using a MULTIPLATE®PLATELET FUNCTION ANALYZER (Roche; Basel, Switzerland) and multiple electrode aggregometry (MEA). This method is recommended for conducting studies on platelets by the Clinical and Laboratory Standards Institute (document H58-A, 2008). The following tests were performed: ADP-induced platelet activation - ADP test;  
Cyclooxygenase dependent aggregation - ASPI test;  
vWf and glycoprotein Ib-dependent aggregation (using ristocetin) - RISTO test; Thrombin receptor activating peptide 6 (TRAP6)-induced activation of thrombin receptor (TRAP test), which is sensitive to IIb/IIIa receptor antagonists

All of the platelet-activity tests were performed 30-180 min after blood collection, as suggested by the manufacturer.

***Statistical analysis***

The Shapiro–Wilk test was used to evaluate the distribution. Because of the non-Gaussian distribution, non-parametric tests were used. Differences in studied variables between groups were tested using the Mann–Whitney *U*-test and ANOVA range Kruskal–Wallis tests for independent groups. The correlations were analyzed with the Spearman rank correlation coefficient of *P <* 0.05 was considered statistically significant. The statistical analysis was performed with STATISTICA 7.0 (StatSoft Polska Sp z o.o., Krakow, Poland). The statistical review of the study was performed by a biomedical statistician.

RESULTS

***Comparison of cirrhotic patients with and without PVT***

A detailed comparison of analyzed groups regarding anthropometric, demographical and basic laboratory parameters is shown in Table 1.

When compared cirrhotic patients with and without PVT, there were significantly increased prothrombin levels in patients with PVT (*P =* 0.01). The TRAP test results were significantly lower in the PVT group (*P =* 0.003). No other differences in coagulation parameters or other platelet activity tests were found the groups. The comparison of analyzed coagulation factors and the results of the platelet activity tests are shown in Table 2.

Omentin serum concentrations were significantly decreased in patients with PVT (*P =* 0.01). There were no significant differences in vaspin levels between the groups. No significant differences were found in terms of diabetes mellitus occurrence, fasting glucose, fasting insulin levels, or HOMA-IR. The details are described in Table 3.

***Results according to Child-Pugh score***

Data comparing patients with various Child-Pugh (C-P) scores are presented in Table 4.

We observed that the APTT was significantly longer in C-P B patients than in the C-P A group. Moreover, D-dimer levels were increased slightly with more severe cases of liver disease. There was a significant decrease in prothrombin activity in more advanced liver disease cases. Von Willebrand factor levels and activity were significantly higher in C-P C group compared to the C-P A group.

No significant differences in platelet activity or adipokines serum levels were found with respect to liver disease severity as assessed with the C-P score.

***Results according to MELD score***

The patients were also divided into two groups based on MELD score (MELD ≤ 18 and > 18). A significantly shorter prothrombin time, activity and INR were confirmed in patients with MELD scores >18. In contrast to the Child-Pugh score, there was a significant increase in the results of the TRAP-, ASPI- and RISTO tests in patients with lower MELD scores. The TRAP test values were higher in patients with less severe liver disease (56.2 *vs* 42.1, *P =* 0.03). The ASPI test (45.9 *vs* 26.4, *P =* 0.001) and RISTO-high test results were also higher in this group (68.5 *vs* 43, *P =* 0.02). On the other hand, von Willebrand factor levels were significantly higher in the MELD > 18 group (Table 5).

There were no significant differences with respect to omentin levels, vaspin levels, or metabolic parameters in the groups of patients with different MELD score.

***Comparison of cirrhotic patients with viral* *vs non-viral and alcoholic* *vs non-alcoholic etiology***

No significant differences were found between patients with viral and non-viral cirrhosis with respect to the analyzed adipokines and metabolic and coagulation factors (Table 6).

When compared to patients with alcoholic and non-alcoholic cirrhosis, prothrombin levels appeared to be higher in the latter. There was no difference in terms of omentin, vaspin, metabolic factors or other coagulation parameters between these two groups (Table 7).

***Comparison of adipokine concentrations in cirrhotic patients with and without diabetes and different HOMA-IR levels***

There was no significant difference in serum omentin or vaspin levels between cirrhotic patients with and without diabetes (991.0 ± 352.7 ng/mL *vs* 1035 ± 330.6 ng/mL, 0.20 ± 0.10 ng/mL *vs* 0.32 ± 0.23 ng/mL, respectively).

When compared cirrhotic patients with HOMA-IR ≤ 3 *vs* > 3, both serum omentin and vaspin levels were significantly down-regulated in patients with better insulin sensitivity (858.2 ± 196.0 ng/mL *vs* 1100.0 ± 355.1 ng/mL, *P =* 0.03; 0.17 ± 0.09 ng/mL *vs* 0.32 ± 0.19 ng/mL, *P =* 0.02, respectively).

***Correlations between coagulation factors, platelet activity tests, metabolic factors, adipokines and clinical outcomes***

A positive relationship between serum omentin and vaspin levels were found both when all of the patients were analyzed (*r =* 0.41; *P =* 0.01) and among those with PVT (*r =* 0.94; *P <* 0.001). In patients without PVT, the results were on the threshold of statistical significance (*P =* 0.05).

We found a positive correlation between insulin and omentin levels in PVT (+) patients (*r =* 0.47; *P =* 0.04). There was significant negative correlation between the presence of diabetes and the results of the platelet activity tests: ADP (*r =* [-0.29]; *P =* 0.04) and RISTO-low (*r =* [0.32]; *P =* 0.02).

Vaspin serum levels were negatively associated with diabetes occurrence (*r =* [-0.64]; *P =* 0.04) and protein C concentration (*r =* [-0.63]; *P =* 0.04). Vaspin levels were positively associated with von Willebrand factor levels (*r =* 0.36; *P =* 0.02). Omentin serum concentrations were positively related to von Willebrand factor levels (*r =* 0.40; *P =* 0.008).

There was no relationship between the grade of esophageal varices and serum vaspin or omentin levels.

**DISCUSSION**

Adipokines, adipose tissue-derived hormones, have been shown to have a variety of local, peripheral and central effects[6]. A growing number of studies show a particularly important role of adipokines in the development of liver damage in a variety of diseases[6,7,27,28]. However, relatively little research has been done concerning the influence of adipokines on the natural history of liver cirrhosis. To the best of our knowledge, this is the first study to assess omentin and vaspin levels in cirrhotic patients with PVT, the diagnosis of which remains challenging. It has been demonstrated that PVT generally coexists with a more severe course of cirrhosis. It is therefore essential to identify patients who are at risk for this complication.

Our study for the first time showed significantly lower levels of serum omentin in cirrhotic patients with PVT. However, omentin serum levels were not associated with the severity of cirrhosis according to either the Child-Pugh or MELD scales. There was also no relationship between omentin and the grade of esophageal varices. Patients with PVT had significantly higher prothrombin concentrations. Prothrombin is a key factor in clot formation, and elevated levels appear to promote venous thrombosis. In the study by Eisinger *et al*[19], omentin levels were significantly higher in the portal vein. In addition, these levels tended to be higher in the hepatic vein and systemic blood of patients with liver cirrhosis compared with the respective blood compartments of control patients with healthy livers. Similar to our results, no association with complications resulting from portal hypertension was observed.

As mentioned above, there are conflicting results regarding omentin synthesis in the liver[14,15]. Our previous study of non-obese CHC patients, 16% of whom were cirrhotic, showed significantly higher omentin serum levels compared to healthy controls. However, omentin serum levels were not associated with any histopathological findings[14].Similar results were found by Nassif *et al*[18]’*s* study, which showed significantly higher serum omentin levels in CHC subjects; however, no information was provided regarding histopathological examination.

In patients with obesity and metabolic syndrome, circulating omentin levels were negatively associated with a multiplicity of metabolic risk factors, suggesting that omentin acts as a biomarker of metabolic disorders[16].IR, which is considered to be negatively associated with serum omentin in patients with metabolic diseases, is commonly present in patients with liver cirrhosis. Therefore, higher serum omentin levels in cirrhotic patients with increased IR is an unexpected finding. However, our results are in accordance with results obtained by Eisinger *et al*[19], who found omentin serum levels to be significantly decreased in cirrhotic patients with better insulin sensitivity.

Nassif *et al*[18] analyzed CHC patients and found a negative correlation between serum omentin and HOMA-IR and fasting glucose, with lower serum omentin levels in subjects with T2DM. However, in those patients, serum omentin concentration was still significantly higher than in diabetic patients without CHC. We must still bear in mind the strong influence of DM and obesity on serum omentin levels[29,30].An additional factor is the direct impact of HCV on inflammatory, metabolic and intracellular insulin pathways[31]. In the present study, there was no difference in serum omentin levels in cirrhotic patients with and without DM. This is an unexpected result considering the negative correlation between serum omentin and metabolic abnormalities in DM and MS. However, the result must be analyzed with caution due to a small number of patients with DM in our group. Nevertheless, in the study by Yilmaz *et al*[32], serum levels of omentin were significantly lower in normal controls compared to non-cirrhotic patients with biopsy-proven NAFLD, 40% of whom were diabetic and over 60% of whom had metabolic syndrome. Moreover, serum omentin appeared to be a predictor of hepatocyte ballooning, independent of potential confounders, including metabolic parameters. This last observation points to a pivotal role omentin in the development and progression of NAFLD.

To exclude a potential influence of HCV on IR and lipid profile, which may interfere with omentin serum levels, we compared cirrhotic patients with CHC to the rest of the study group. There were no significant differences between these two subgroups in terms of serum omentin, glucose and fasting insulin, HOMA-IR, cholesterol, coagulation factors or platelet activity.

The top three causes of cirrhosis in our study were alcoholic liver disease, CHC and autoimmune hepatitis. There were no differences in serum omentin levels in patients with viral or toxic cirrhosis compared to the rest of analyzed group. In the study by Eisinger *et al.*, only three patients out of 34 had cirrhosis due to CHC[19]. The comparison between our study and Nassiff *et al*[18]*’s* study is also difficult because no information was provided regarding the viral genotype and fibrosis stage in the analyzed patients. Therefore, the discrepancy in the obtained results regarding the relationship between serum omentin and insulin sensitivity may result from different study group characteristics.

In terms of to higher serum omentin levels in patients with CLDs, the question arises of whether these increased levels result from the impaired metabolism of this adipokine in the inflamed and fibrotic liver. However, our study did not show any difference in serum omentin concentrations in more advanced cirrhosis (*i.e*., more impaired liver function), suggesting no significant influence of hepatic metabolism on the levels of this adipokine. Therefore, further questions remain as to whether omentin expression in the liver is an important source of the serum levels of this adipokine. Our previous study confirmed omentin liver expression. However, hepatic gene expression was not associated with its serum levels or any histopathological feature. Moreover, omentin was not up-regulated in cirrhosis[14].

The dysfunction of SECs in cirrhotic liver is strictly associated with a low production of vasodilators, such as nitric oxide, which increases intrahepatic resistance and portal hypertension[33,34]. Nitric oxide is a central molecule in the regulation of vascular tone by regulating eNOS activity in blood vessels[35].Omentin was found to mediate endothelium relaxation by up-regulating eNOS activity[12]. Omentin has also been described as a potent anti-inflammatory adipokine, inhibiting TNF alpha-mediated phosphorylation of p38 kinase and Jun kinase in vascular smooth muscle cells. Therefore, higher omentin levels in patients with cirrhosis may be a compensatory mechanism against intrahepatic resistance.

Vaspin is another novel adipokine that is primarily produced by visceral and subcutaneous adipose tissue. The current study for the first time compared serum vaspin levels in cirrhotic patients with and without PVT and did not find any difference between these groups. Our previous study in CHC patients suggested serum vaspin to be a potential predictor of advanced liver fibrosis, with evident increases in subjects with advanced fibrosis[21]. However, in patients with insignificant fibrosis, serum vaspin level were significantly lower than in controls. Similarly, serum vaspin levels were lower in NAFLD patients with simple steatosis compared to healthy controls, with a subsequent increase in patients with NASH and ballooning degeneration[23].The study by Aktas *et al*[24] confirmed serum vaspin to be a predictor of liver fibrosis in NAFLD, independently of potential confounders, including metabolic parameters.Moreover, vaspin serum levels reflected the intensity of hepatic angiogenesis in CHC patients, a phenomenon that aggravates CLDs progression[22]. It is well established that active fibrogenesis and angiogenesis are connected with the progression of portal hypertension, an undisputed risk factor of PVT. In the present study, there was no difference in vaspin serum levels between patients with different stages of cirrhosis according to Child-Pugh and MELD scores. This is in accordance with previous results showing that there is no further increase in vaspin serum levels when advanced fibrosis appears.

Visceral vaspin expression significantly correlated with BMI, percentage of body fat and the levels of plasma glucose. As vaspin has been found to be a compensatory adipokine in IR, a common metabolic disorder in patients with cirrhosis, serum vaspin is expected to be higher in patients with worsen insulin sensitivity. As expected, the present study revealed significantly higher serum vaspin levels in patients with HOMA-IR ≥ 3. The results are in accordance with our previous study in CHC patients, which showed HOMA-IR to be significantly higher in patients with fibrosis and to correlate with fibrosis stage. In contrast, serum vaspin levels tended to be increased in patients with HOMA-IR ≥ 3[37].Bearing in mind a direct influence of HCV on insulin sensitivity, further analysis comparing serum vaspin levels in groups of patients with viral and non-viral cirrhosis was carried out. However, no significant differences were observed between these two subgroups of cirrhotic patients. Similarly, no difference was detected when comparing patients with toxic and non-toxic cirrhosis. These observation support the opinion that increased serum vaspin levels may be a compensatory mechanism to abolish IR.

Recently, vaspin has been found to exert antiatherogenic actions. Vaspin decreased the levels of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of all types of nitric oxide synthases (NOSs), and activated dimethylarginine dimethylaminohydrolase (DDAH), an enzyme that metabolizes ADMA to citrulline and dimethylamine. Elevated ADMA has been shown to attenuate endothelium-dependent vasodilation in humans[38] and, together with dysregulation of DDAH, is involved in endothelial dysfunction in hypercholesterolemia and diabetes. Some recent evidence has indicated that DDAH activity is impaired by oxidative stress, permitting ADMA to accumulate[39].Considering the beneficial effect of vaspin on IR and oxidative stress, it may act as a compensatory and protective factor. Unfortunately, our study did not reveal any difference in vaspin serum levels between cirrhotic patients with and without PVT, and there was no relationship with the grade of esophageal varices. The evident limitation of our study is the lack of portal pressure measurement; therefore, the interpretation of the presented results should be performed with caution.

As mentioned above, PVT is more frequently observed in later stages of cirrhosis. However, the development of PVT is unpredictable, and its risk factors are not well characterized. According to Virchow’s triad principle, a venous thrombosis results from the coexistence of blood flow abnormalities, endothelial injury and hypercoagulation. For these reasons, PVT in cirrhosis could be linked with endotoxemia, thrombophilia and portal hypertension. Alternatively, PVT it may have no definite association with any of these factors. Advanced cirrhosis is associated with profound and complex coagulation defects, with concomitant defective fibrinolysis and impaired synthesis of thromboxane A2 and serotonin by platelets. The final result of all of these disturbances is a promotion of a prothrombotic state, likely related to up-regulated endothelial synthesis of von Willebrand factor (vWf) and increased levels of VIII factor. These effects occur in combination with low levels of hepatic anticoagulation agents, such as antithrombin III and proteins C and S[40,41].vWf levels and the VIII factor-to-PC ratio are as predictive of mortality as MELD. Thrombogenic mechanisms that operate within the cirrhotic liver might underlie the progression of portal hypertension and adverse clinical outcomes in patients with cirrhosis[42].

Our study revealed prothrombin concentration to be significantly higher in patients with PVT. Prothrombin is an essential agent that participates in clot formation. Elevated levels of this factor lead to thrombin formation, inhibit the activity of antithrombotic protein S, and promote venous thrombosis in the presence of endothelial injury[43,44]. On the other hand, in our study, protein C levels tended to be lower in PVT patients, although the difference did not reach statistical significance.

The loss of platelet inhibition by insulin has been suggested to be a major determinant of platelet hyperactivity during obesity. Low levels of HDL-cholesterol promote platelet activation and aggregation, possibly because HDL antagonizes the stimulating properties of LDL on platelets[45].In agreement with these facts, we found that not HDL-cholesterol but also LDL-cholesterol and total blood cholesterol levels were markedly diminished in patients with PVT; however, the difference was not statistically significant. The roles of omentin and vaspin in decreasing IR and oxidative stress may exert a protective effect against platelet hyperreactivity. Unfortunately, serum omentin was not associated with platelet hyperactivity. On the other hand, both serum omentin and vaspin concentrations, in addition to fasting insulin, were positively related to vWF level and activity.

However, the tendency of patients with liver disease to bleed and to experience thrombus formation cannot be explained solely by alterations in hemostasis. A partial explanation of hemorrhagic and thrombotic events in patients with advanced CLDs or cirrhosis result from complex hemodynamic alterations, such as portal hypertension, endothelial dysfunction, kidney dysfunction, and the release of substances similar to heparin by bacterial[46].

The last intriguing observation of the study, which has not been previously described, is a positive association between serum omentin and vaspin. As mentioned above, ADMA, an endogenous inhibitor of NOS, is increased in the serum of patients with liver cirrhosis compared with healthy controls and may antagonize peripheral vasodilatation. High intrahepatic ADMA levels may aggravate intrahepatic resistance[47,48. The ability of vaspin and omentin to enhance eNOS activity and to down-regulate ADMA production may be a compensatory and protective mechanism against portal hypertension. The positive mutual correlation between both adipokines may suggest a collaborative action of both adipokines, not only as compensatory agents in portal hypertension but also in insulin resistance, oxidative stress and inflammation.

There are some evident limitations of our study. First, the group of patients is relatively small and not homogenous. Second, no liver biopsy was carried out, and the measurement of collagen proportionate area, which may reflect the severity of cirrhosis and predict portal hypertension, was not applicable. Third, no measurement of portal pressure was made, so a direct assessment of how omentin and vaspin may influence vasodilatation or vasoconstriction was not possible. Fourth, the relationship between PVT and the levels of omentin is a simple association and not a cause-effect relationship. A follow-up study should have been designed to demonstrate that decreased omentin levels are related to a higher risk of developing PVT.

In conclusion, our study showed serum omentin but not vaspin levels to be significantly higher in cirrhotic patients with PVT. Moreover, omentin and vaspin concentrations were higher in cirrhotic patients with increased IR. Neither omentin nor vaspin were associated with other metabolic abnormalities, including DM. The origin of liver cirrhosis and grade of liver impairment as assessed by the Child-Pugh or MELD scores were not correlated with omentin or vaspin levels. There was no relationship between platelet hyperactivity and the serum levels of either analyzed adipokine. The positive mutual correlation between omentin and vaspin may suggest their collaborative action against IR, inflammation and portal hypertension. Our results indicate that although omentin and vaspin could be involved into the pathophysiology of the development of cirrhosis, they are not good indicators of its origin or severity and do not impact the thrombotic activity of platelets.

Additional studies must delineate whether the levels of omentin and vaspin play a pivotal, protective role in liver cirrhosis against PVT and portal hypertension.

**COMMENTS**

***Background***

Ongoing research has revealed alterations in the levels and expression of various adipokines in cirrhosis. Portal vein thrombosis (PVT) has been considered to be a complication of more advanced liver cirrhosis. The data regarding novel adipokines in liver cirrhosis is scare and ambiguous. The current study evaluated the serum concentrations of omentin and vaspin in patients with liver cirrhosis of different origins and stages with and without PVT. The relationships of these measures with disease severity and etiology, platelet activity, hemostatic parameters and potential complications were also assessed

***Research frontiers***

Accumulating data suggest that obesity and insulin resistance are related to a more rapid progression of chronic liver diseases, the development of cirrhosis and its complications. Some adipokines have been suggested to contribute to the complicated pathophysiology of hepatic injury and repair. Moreover, there is some data suggesting, that omentin plays role in regulating endothelial homeostasis.

***Innovations and breakthroughs***

This study showed serum omentin levels to be significantly higher in cirrhotic patients with PVT. This finding confirms important role of this adipokine in vessel homeostasis. Serum levels of omentin and vaspin seem not to be associated with platelet hyperactivity.

***Application***

The presented study suggests that there is a need of further studies on the role of novel adipokines in liver cirrhosis and its complications as liver failure is strictly connected to metabolism disturbance.

***Peer-review***

Interesting and certainly new topic describing two novel adipokines – omentin and vaspin in patients with liver cirrhosis with and without PVT. The study provides analysis of relationship between adipokines serum levels and disease severity and etiology,, metabolic abnormalities and platelets activity.

## REFERENCES

1 **Bayraktar Y**, Harmanci O. Etiology and consequences of thrombosis in abdominal vessels. *World J Gastroenterol* 2006; **12**: 1165-1174 [PMID: 16534866]

2 **Ogren M**, Bergqvist D, Björck M, Acosta S, Eriksson H, Sternby NH. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. *World J Gastroenterol* 2006; **12**: 2115-2119 [PMID: 16610067]

3 **Francoz C**, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B, Denninger MH, Sauvanet A, Valla D, Durand F. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. *Gut* 2005; **54**: 691-697 [PMID: 15831918 DOI: 10.1136/gut.2004.042796]

4 **Ravaioli M**, Zanello M, Grazi GL, Ercolani G, Cescon M, Del Gaudio M, Cucchetti A, Pinna AD. Portal vein thrombosis and liver transplantation: evolution during 10 years of experience at the University of Bologna. *Ann Surg* 2011; **253**: 378-384 [PMID: 21183851 DOI: 10.1097/SLA.0b013e318206818b]

5 **Bosch J**, García-Pagán JC. Complications of cirrhosis. I. Portal hypertension. *J Hepatol* 2000; **32**: 141-156 [PMID: 10728801]

6 **Kalafateli M**, Triantos C, Tsochatzis E, Michalaki M, Koutroumpakis E, Thomopoulos K, Kyriazopoulou V, Jelastopulu E, Burroughs A, Lambropoulou-Karatza C, Nikolopoulou V. Adipokines levels are associated with the severity of liver disease in patients with alcoholic cirrhosis. *World J Gastroenterol* 2015; **21**: 3020-3029 [PMID: 25780301 DOI: 10.3748/wjg.v21.i10.3020]

7 **Kukla M**, Mazur W, Bułdak RJ, Zwirska-Korczala K. Potential role of leptin, adiponectin and three novel adipokines--visfatin, chemerin and vaspin--in chronic hepatitis. *Mol Med* 2011; **17**: 1397-1410 [PMID: 21738955 DOI: 10.2119/molmed.2010.00105]

8 **Elpek GÖ**. Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update. *World J Gastroenterol* 2014; **20**: 7260-7276 [PMID: 24966597 DOI: 10.3748/wjg.v20.i23.7260]

9 **Wallace AM**, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, Sattar N. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). *Circulation* 2001; **104**: 3052-3056 [PMID: 11748099]

10 **Wolk R**, Berger P, Lennon RJ, Brilakis ES, Johnson BD, Somers VK. Plasma leptin and prognosis in patients with established coronary atherosclerosis. *J Am Coll Cardiol* 2004; **44**: 1819-1824 [PMID: 15519013 DOI: 10.1016/j.jacc.2004.07.050]

11 **Ueno T**, Nakamura A, Nakayama H, Otabe S, Yuan X, Fukutani T, Iwamoto H, Nakamura T, Koga H, Torimura T, Sata M, Yamada K. Adiponectin suppresses endoplasmic reticulum stress in nonalcoholic steatohepatitis. *Exp Ther Med* 2011; **2**: 1035-1040 [PMID: 22977616 DOI: 10.3892/etm.2011.348]

12 **Yamawaki H**, Tsubaki N, Mukohda M, Okada M, Hara Y. Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. *Biochem Biophys Res Commun* 2010; **393**: 668-672 [PMID: 20170632 DOI: 10.1016/j.bbrc.2010.02.053]

13 **Maruyama S**, Shibata R, Kikuchi R, Izumiya Y, Rokutanda T, Araki S, Kataoka Y, Ohashi K, Daida H, Kihara S, Ogawa H, Murohara T, Ouchi N. Fat-derived factor omentin stimulates endothelial cell function and ischemia-induced revascularization via endothelial nitric oxide synthase-dependent mechanism. *J Biol Chem* 2012; **287**: 408-417 [PMID: 22081609 DOI: 10.1074/jbc.M111.261818]

14 **Kukla M**, Waluga M, Adamek B, Zalewska-Ziob M, Kasperczyk J, Gabriel A, Bułdak RJ, Sobala-Szczygieł B, Kępa L, Ziora K, Żwirska-Korczala K, Surma E, Sawczyn T, Hartleb M. Omentin serum concentration and hepatic expression in chronic hepatitis C patients - together or apart? *Pol J Pathol* 2015; **66**: 231-238 [PMID: 26619101]

15 **Yang RZ**, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, Shuldiner AR, Fried SK, McLenithan JC, Gong DW. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. *Am J Physiol Endocrinol Metab* 2006; **290**: E1253-E1261 [PMID: 16531507 DOI: 10.1152/ajpendo.00572.2004]

16 **Shibata R**, Ouchi N, Takahashi R, Terakura Y, Ohashi K, Ikeda N, Higuchi A, Terasaki H, Kihara S, Murohara T. Omentin as a novel biomarker of metabolic risk factors. *Diabetol Metab Syndr* 2012; **4**: 37 [PMID: 22835063 DOI: 10.1186/1758-5996-4-37]

17 **Pan HY**, Guo L, Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. *Diabetes Res Clin Pract* 2010; **88**: 29-33 [PMID: 20129687 DOI: 10.1016/j.diabres.2010.01.013]

18 **Nassif WM**, Amin AI, Hassan ZA, Abdelaziz DH. Changes of serum omentin-1 levels and relationship between omentin-1 and insulin resistance in chronic hepatitis C patients. *EXCLI J* 2013; **12**: 924-932 [PMID: 27092037]

19 **Eisinger K**, Krautbauer S, Wiest R, Karrasch T, Hader Y, Scherer MN, Farkas S, Aslanidis C, Buechler C. Portal vein omentin is increased in patients with liver cirrhosis but is not associated with complications of portal hypertension. *Eur J Clin Invest* 2013; **43**: 926-932 [PMID: 23855493 DOI: 10.1111/eci.12122]

20 **Klöting N**, Berndt J, Kralisch S, Kovacs P, Fasshauer M, Schön MR, Stumvoll M, Blüher M. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. *Biochem Biophys Res Commun* 2006; **339**: 430-436 [PMID: 16298335 DOI: 10.1016/j.bbrc.2005.11.039]

21 **Kukla M**, Waluga M, Sawczyn T, Berdowska A, Kajor M, Boryczka G, Stygar D, Gabriel A, Zwirska-Korczala K, Hartleb M. Serum vaspin may be a good indicator of fibrosis in chronic hepatitis C and is not altered by antiviral therapy. *Pol J Pathol* 2012; **63**: 213-220 [PMID: 23359189]

22 **Kukla M**, Berdowska A, Gabriel A, Sawczyn T, Mazur W, Sobala-Szczygieł B, Grzonka D, Zajęcki W, Tomaszek K, Bułdak RJ, Zwirska-Korczala K. Association between hepatic angiogenesis and serum adipokine profile in non-obese chronic hepatitis C patients. *Pol J Pathol* 2011; **62**: 218-228 [PMID: 22246907]

23 **Kukla M**, Zwirska-Korczala K, Hartleb M, Waluga M, Chwist A, Kajor M, Ciupinska-Kajor M, Berdowska A, Wozniak-Grygiel E, Buldak R. Serum chemerin and vaspin in non-alcoholic fatty liver disease. *Scand J Gastroenterol* 2010; **45**: 235-242 [PMID: 20095887 DOI: 10.3109/00365520903443852]

24 **Aktas B**, Yilmaz Y, Eren F, Yonal O, Kurt R, Alahdab YO, Celikel CA, Ozdogan O, Imeryuz N, Kalayci C, Avsar E. Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease. *Metabolism* 2011; **60**: 544-549 [PMID: 20580037 DOI: 10.1016/j.metabol.2010.05.008]

25 **Kamath PS**, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. *Hepatology* 2001; **33**: 464-470 [PMID: 11172350 DOI: 10.1053/jhep.2001.22172]

26 **Tang Q**, Li X, Song P, Xu L. Optimal cut-off values for the homeostasis model assessment of insulin resistance (HOMA-IR) and pre-diabetes screening: Developments in research and prospects for the future. *Drug Discov Ther* 2015; **9**: 380-385 [PMID: 26781921 DOI: 10.5582/ddt.2015.01207]

27 **Tsochatzis EA**, Papatheodoridis GV, Archimandritis AJ. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. *Mediators Inflamm* 2009; **2009**: 831670 [PMID: 19753129 DOI: 10.1155/2009/831670]

28 **Kasztelan-Szczerbinska B**, Surdacka A, Slomka M, Rolinski J, Celinski K, Smolen A, Szczerbinski M. Association of serum adiponectin, leptin, and resistin concentrations with the severity of liver dysfunction and the disease complications in alcoholic liver disease. *Mediators Inflamm* 2013; **2013**: 148526 [PMID: 24259947 DOI: 10.1155/2013/148526]

29 **de Souza Batista CM**, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, Ndubuizu K, Patil S, Schwartz A, Kligman M, Fried SK, Gong DW, Shuldiner AR, Pollin TI, McLenithan JC. Omentin plasma levels and gene expression are decreased in obesity. *Diabetes* 2007; **56**: 1655-1661 [PMID: 17329619 DOI: 10.2337/db06-1506]

30 **Auguet T**, Quintero Y, Riesco D, Morancho B, Terra X, Crescenti A, Broch M, Aguilar C, Olona M, Porras JA, Hernandez M, Sabench F, del Castillo D, Richart C. New adipokines vaspin and omentin. Circulating levels and gene expression in adipose tissue from morbidly obese women. *BMC Med Genet* 2011; **12**: 60 [PMID: 21526992 DOI: 10.1186/1471-2350-12-60]

31 **Knobler H**, Schihmanter R, Zifroni A, Fenakel G, Schattner A. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. *Mayo Clin Proc* 2000; **75**: 355-359 [PMID: 10761489 DOI: 10.4065/75.4.355]

32 **Yilmaz Y**, Yonal O, Kurt R, Alahdab YO, Eren F, Ozdogan O, Celikel CA, Imeryuz N, Kalayci C, Avsar E. Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease. *Scand J Gastroenterol* 2011; **46**: 91-97 [PMID: 20809771 DOI: 10.3109/00365521.2010.516452]

33 **Iwakiri Y**. Endothelial dysfunction in the regulation of cirrhosis and portal hypertension. *Liver Int* 2012; **32**: 199-213 [PMID: 21745318 DOI: 10.1111/j.1478-3231.2011.02579.x]

34 **Wiest R**. Splanchnic and systemic vasodilation: the experimental models. *J Clin Gastroenterol* 2007; **41 Suppl 3**: S272-S287 [PMID: 17975477 DOI: 10.1097/MCG.0b013e318157cb57]

35 **Zipprich A**. Hemodynamics in the isolated cirrhotic liver. *J Clin Gastroenterol* 2007; **41 Suppl 3**: S254-S258 [PMID: 17975473 DOI: 10.1097/MCG.0b013e318150d3b5]

36 **Kazama K**, Usui T, Okada M, Hara Y, Yamawaki H. Omentin plays an anti-inflammatory role through inhibition of TNF-α-induced superoxide production in vascular smooth muscle cells. *Eur J Pharmacol* 2012; **686**: 116-123 [PMID: 22554771 DOI: 10.1016/j.ejphar.2012.04.033]

37 **Kukla M**, Zwirska-Korczala K, Gabriel A, Waluga M, Warakomska I, Szczygiel B, Berdowska A, Mazur W, Wozniak-Grygiel E, Kryczka W. Chemerin, vaspin and insulin resistance in chronic hepatitis C. *J Viral Hepat* 2010; **17**: 661-667 [PMID: 20002564 DOI: 10.1111/j.1365-2893.2009.01224.x]

38 **Böger RH**. Association of asymmetric dimethylarginine and endothelial dysfunction. *Clin Chem Lab Med* 2003; **41**: 1467-1472 [PMID: 14656027 DOI: 10.1515/CCLM.2003.225]

39 **Lin KY**, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, Tsuji H, Reaven GM, Cooke JP. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. *Circulation* 2002; **106**: 987-992 [PMID: 12186805]

40 **Ordinas A**, Escolar G, Cirera I, Viñas M, Cobo F, Bosch J, Terés J, Rodés J. Existence of a platelet-adhesion defect in patients with cirrhosis independent of hematocrit: studies under flow conditions. *Hepatology* 1996; **24**: 1137-1142 [PMID: 8903388 DOI: 10.1053/jhep.1996.v24.pm0008903388]

41 **Ferro D**, Quintarelli C, Lattuada A, Leo R, Alessandroni M, Mannucci PM, Violi F. High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia. *Hepatology* 1996; **23**: 1377-1383 [PMID: 8675154 DOI: 10.1002/hep.510230613]

42 **Kalambokis GN**, Oikonomou A, Christou L, Kolaitis NI, Tsianos EV, Christodoulou D, Baltayiannis G. von Willebrand factor and procoagulant imbalance predict outcome in patients with cirrhosis and thrombocytopenia. *J Hepatol* 2016; **65**: 921-928 [PMID: 27297911 DOI: 10.1016/j.jhep.2016.06.002]

43 **Wolberg AS**, Monroe DM, Roberts HR, Hoffman M. Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk. *Blood* 2003; **101**: 3008-3013 [PMID: 12506014 DOI: 10.1182/blood-2002-08-2527]

44 **Seré KM**, Rosing J, Hackeng TM. Inhibition of thrombin generation by protein S at low procoagulant stimuli: implications for maintenance of the hemostatic balance. *Blood* 2004; **104**: 3624-3630 [PMID: 15292065 DOI: 10.1182/blood-2004-03-1146]

45 **Korporaal SJ**, Akkerman JW. Platelet activation by low density lipoprotein and high density lipoprotein. *Pathophysiol Haemost Thromb* 2006; **35**: 270-280 [PMID: 16877876 DOI: 10.1159/000093220]

46 **Hodge A**, Crispin P. Coagulopathy in liver disease: the whole is greater than the sum of its parts. *J Gastroenterol Hepatol* 2010; **25**: 1-2 [PMID: 20136967 DOI: 10.1111/j.1440-1746.2009.06027.x]

47 **Mookerjee RP**, Vairappan B, Jalan R. The puzzle of endothelial nitric oxide synthase dysfunction in portal hypertension: The missing piece? *Hepatology* 2007; **46**: 943-946 [PMID: 17879360 DOI: 10.1002/hep.21905]

48 **Nijveldt RJ**, Teerlink T, Siroen MP, van Lambalgen AA, Rauwerda JA, van Leeuwen PA. The liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA). *Clin Nutr* 2003; **22**: 17-22 [PMID: 12553945]

**P-Reviewer:** Khayyat YM, La Mura V, StromSC **S-Editor:** Yu J **L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Poland

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0

**Table 1 General characteristics and basic laboratory tests of cirrhotic patients with and without portal vein thrombosis**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **All patients**  ***n =* 51** | **PVT (+)**  ***n =* 17** | **PVT (-)**  ***n =* 34** | ***P value*** |
| Sex (M/F), *n* (%) | 35/16  (68.6/31.4) | 12/5 (70.6/29.4) | 23/11 (67.6/32.4) | *P >* 0.05 |
| Age(years) | 52 (26-80) | 56 (26-80) | 54 (27-68) | *P >* 0.05 |
| BMI (kg/m2) | 27 (17-40) | 27 (20-40) | 27 (17-36) | *P >* 0.05 |
| Child-Pugh (points) | 7.7 (5-12) | 7.3 (5-11) | 7.9 (5-12) | *P >* 0.05 |
| MELD score (points) | 13.9 (6-26) | 12.8 (9-22) | 14.5 (6-26) | *P >* 0.05 |
| Bilirubin (mg/dL) | 3.4 (0.6-14.3) | 2.3 (1.1-4.8) | 3.9 (0.6-14.3) | *P >* 0.05 |
| Hemoglobin (g/dL) | 7.5-15.3 | 11.9 (8.4-15) | 12.2 (7.5-15.3) | *P >* 0.05 |
| Platelets (× 103 /mm3) | 96 (18-330) | 83 (32-149) | 103 (18-330) | *P >* 0.05 |
| WBC (× 103 /mm3) | 5.1 (1.3-15.3) | 4.3 (1.9-11.2) | 5.5 (1.3-15.3) | *P >* 0.05 |
| Albumin (g/dL) | 3.2 (1.7-5.1) | 3.2 (2.4-4.3) | 3.2 (1.7-5.1) | *P >* 0.05 |
| ALT (U/L) | 39 (15-130) | 41.6 (15-130) | 38.1 (15-115) | *P >* 0.05 |
| AST (U/L) | 71.2 (18-216) | 69 (18-164) | 72.1 (20-216) | *P >* 0.05 |
| GGTP (U/L) | 122 (25-489) | **180.3 (25-489)1** | **91.2 (13-236)** | ***P =* 0.02** |
| Cholesterol (mg/dL) | 176 (45-409) | 147.8 (45-284) | 187 (87-409) | *P >* 0.05 |
| HDL-Ch (mg/dL) | 46.2 (13-78) | 33.6 (17-45) | 49.6 (13-78) | *P >* 0.05 |
| LDL-Ch (mg/dL) | 97.5 (19-203) | 83 (19-171) | 102.4 (43-203) | *P >* 0.05 |
| TG (mg/dL) | 127 (47-407) | 133.3 (47-341) | 125.3 (48-407) | *P >* 0.05 |
| Ascites | 19/51 (42%) | 8/17 (47%) | 15/34 (44%) | *P >* 0.05 |

1GGTP level was significantly higher in PVT (+) patients. *P* value < 0.05 was considered statistically significant. The data are shown as the mean and range or percentage where applicable. BMI: Body mass index; TG: Triglycerides.

**Table 2 Coagulation parameters and platelet activity tests in cirrhotic patients with or without portal vein thrombosis**

*P* value < 0.05 was considered statistically significant. The data are shown as the mean and range or percentage where applicable. PT: Prothrombin time; INR: International normalized ratio.

|  |  |  |  |
| --- | --- | --- | --- |
|  | **PVT (+)**  ***n* = 17** | **PVT (-)**  ***n =* 34** | ***P* value** |
| PT (s) | 15.5 (12.5-21.9) | 16.8 (11.3-44) | *P >* 0.05 |
| Prothrombin activity (%) | 67.8 (41-92) | 66.5 (36-106) | *P >* 0.05 |
| INR | 1.37 (1.11-1.9) | 1.36 (1-2.19) | *P >* 0.05 |
| APTT | 35.5 (29.1-57) | 34.4 (23.6-49.4) | *P >* 0.05 |
| TRAP test | **37.2 (12-113)** | **55.6 (16-156)** | ***P =* 0.03** |
| ASPI test | 29.1 (5-108) | 40.5 (5-130) | *P >* 0.05 |
| ADP test | 25.8 (1-94) | 34.5 (5-99.9) | *P >* 0.05 |
| RISTO low test | 9.5 (1-35) | 11.6 (0-33) | *P >* 0.05 |
| RISTO high test | 46.4 (5-162) | 61.5 (4-156) | *P >* 0.05 |
| D-dimer (mg/L) | 4434 (663-9455) | 3134 (563-11026) | *P >* 0.05 |
| Protein C (%) | 56.9 (38.1-90.3) | 65.1 (20.9-177.5) | *P >* 0.05 |
| Prothrombin (µg/mL) | **175.6 (71-390)** | **117.4 (36-422)** | ***P* = 0.01** |
| von Willebrand factor (mU/mL) | 1872 (1328-2339) | 1906 (981-2372) | *P >* 0.05 |
| von Willebrand factor activity (IU/mL) | 3.75 (1.72-6.61) | 4.01 (1.01-7.71) | *P >* 0.05 |

Table 3 **Adipokine serum levels, insulin resistance profile and diabetes occurrence in cirrhotic patients with and without portal vein thrombosis**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **PVT (+)**  ***n =* 17** | **PVT (-)**  ***n =* 34** | ***P* value** |
| Diabetes, *n* (%) | 5/17 (29%) | 10/34 (29%) | *P >* 0.05 |
| Glucose (mg/Dl)  (N:75-115 mg/dL) | 128.4 (86-309) | 122.8 (82-430) | *P >* 0.05 |
| Insulin (μIU/mL) | 19.5 (8.7-41.7) | 17.8 (6.1-47.6) | *P >* 0.05 |
| HOMA-IR | 6.6 (2.5-14.1) | 5.3 (0.9-13.4) | *P >* 0.05 |
| Omentin (ng/mL) | **855 (579-1205)** | **1105 (619-2208)** | ***P =* 0.01** |
| Vaspin (ng/mL) | 0.31 (0.09-0.84) | 0.27 (0.09-0.78) | *P >* 0.05 |

*P* values < 0.05 were considered statistically significant.

**Table 4 Coagulation factors and platelet activity test results with regards to the severity of cirrhosis, as assessed according to the Child-Pugh score**

|  | All patients (*n =* 51) | Child-Pugh A  (*n =* 16) | Child-Pugh B  (*n =* 25) | Child-Pugh C  (*n =* 10) |
| --- | --- | --- | --- | --- |
| Thrombosis | 17/51 (33%) | 6/16 (37.5%) | 9/25 (24%) | 2/10 (20%) |
| PT (s) | 13.8 (11.3-44) | **13.8 (11.3-16.9)** | **16.7 (11.3-44)A,C** | **19.2 (14.1-24.4)A,B** |
| Prothrombin activity (%) | 67 (36-106) | **79.2 (58-106)** | **65.4 (43-95)A,C** | **51.4 (36-73)A,B** |
| INR | 1.3 (1-2.2) | **1.2 (1-1.5)** | **1.4 (1.1-2)A,C** | **1.7 (1.2-2.2)A,B** |
| APTT | 34.7 (23.6-57) | **32.3 (23.6-47.4)** | **36.2 (29.1-57)A** | 35.6 (28.2-44) |
| TRAP test | 49.6 (12-156) | 54.5 (15-156) | 43.5 (12-98) | 53.3 (16-113) |
| ASPI test | 36.8 (5-130) | 45.6 (10-130) | 32.3 (5-110) | 34.2 (5-108) |
| ADP test | 31.6 (1-99.9) | 36.3 (13-99.9) | 25.8 (1-77) | 38.4 (9-94) |
| RISTO low test | 10.9 (0-35) | 10.5 (1-25) | 8.9 (0-26) | 16.4 (2-35) |
| RISTO high test | 56.5 (4-162) | 65.5 (7-152) | 41 (4-156) | 60.49 (17-162) |
| D-dimer (mg/L) | 3568 (563-11026) | **2521 (563-9455)** | **3243 (795-8790)C** | **6053 (724-11026)A,B** |
| Protein C (%) | 56.5 (20.9-177.5) | 60.9 (49.1-105.1) | 60.8 (20.9-177.5) | 58.3 (29.4-121.1) |
| Prothrombin (µg/mL) | 136.8 (36-422) | 128.9 (43.1-390) | 152.1 (36-422) | 110.2 (60.4-194) |
| vWf (mU/mL) | 1941 (981-2372) | **1789 (986-2372)** | 1941 (981-2339) | **2062 (1450-2311)A** |
| vWf activity (IU/mL) | 3.8 (1-7.7) | **3.3 (1.5-7.6)** | 3.8 (1-7.7) | **4.8 (2.6-6.6)A** |
| Omentin (ng/mL) | 1023 (579-2208) | 942 (635-1432) | 964 (579-2208) | 1102 (657-1571) |
| Vaspin (ng/mL) | 0.29 (0.1-0.8) | 0.2 (0.1-0.6) | 0.3 (0.1-0.8) | 0.4 (0.1-0.7) |

*P* value < 0.05 was considered statistically significant. The data are shown as the mean and range or percentage where applicable. A: significantly different *vs* Child-Pugh A group; B: significantly different *vs* Child-Pugh B group; C:significantly different *vs* Child-Pugh C group. PT: Prothrombin time; INR: International normalized ratio; vWf: von Willebrand factor.

**Table 5 Coagulation factors and platelet activity test with regards to the severity of cirrhosis, as evaluated according to the MELD score**

|  | All patients (*n =* 51) | MELD < 18  (*n =* 28) | MELD ≥ 18  (*n =* 23) |
| --- | --- | --- | --- |
| Thrombosis | 17/51 (33%) | 11/28 (39.2%) | *7*/23 (30.4%) |
| PT (s) | 13.8 (11.3-44) | **14.1 (11.3-21)** | **19.1 (13.4.-44)\*** |
| Prothrombin activity (%) | 67 (36-106) | **76.4 (43-106)** | **55.6 (36-86)1** |
| INR | 1.3 (1-2.2) | **1.3 (1-1.5)** | **1.6 (1.2-2.2)\*** |
| APTT | 34.7 (23.6-57) | 35.1 (23.6-57) | 34.4 (28.2-44.9) |
| TRAP test | 49.6 (12-156) | **56.2 (15-156)** | **42.1 (12-113)1** |
| ASPI test | 36.8 (5-130) | **45.9 (10-130)** | **26.4 (5-108)1** |
| ADP test | 31.6 (1-99.9) | 36.2 (7-99.9) | 26.5 (1-94) |
| RISTO low test | 10.9 (0-35) | 10.6 (1-25) | 11.3 (0-35) |
| RISTO high test | 56.5 (4-162) | **68.5 (7-156)** | **43 (4-162)1** |
| D-dimer (mg/L) | 3568 (563-11026) | 3094 (563-9455) | 4144 (724-11026) |
| Protein C (%) | 56.5 (20.9-177.5) | 58.7 (20.9-105.1) | 66.7 (29.4-177.5) |
| Prothrombin (µg/mL) | 136.8 (36-422) | 143.6 (36-390) | 128.5 (59-422) |
| vWf (mU/mL) | 1941 (981-2372) | **1841 (986-2372)** | **2006 (981-2311)1** |
| vWf (IU/mL) | 3.8 (1-7.7) | 3.7 (1.5-7.6) | 4.2 (1-7.7) |
| Omentin (ng/mL) | 1023 (579-2208) | 948 (579-1432) | 1110 (619-2208) |
| Vaspin (ng/mL) | 0.29 (0.1-0.8) | 0.25 (0.1-0.8) | 0.32 (0.1-0.8) |

1*P* value < 0.05 was considered statistically significant. MELD ≤ 18 *vs* MELD > 18. The data are shown as the mean and range or percentage where applicable. PT: Prothrombin time; INR: International normalized ratio; vWf: von Willebrand factor.

**Table 6 Coagulation factors, platelet activity tests and adipokines levels with regards to the presence of chronic hepatitis C**

|  | All patients  (*n =* 51) | HCV (+)  (*n =* 15) | HCV (-)  (*n =* 36) |
| --- | --- | --- | --- |
| Thrombosis | 17/51 (33%) | 3/11 (27.3%) | 14/40 (35%) |
| PT (s) | 13.8 (11.3-44) | 14.5 (11.3-19.9) | 16.8 (11.3-44) |
| Prothrombin activity (%) | 67 (36-106) | 72.1 (47-94) | 65.6 (36-106) |
| INR | 1.3 (1-2.2) | 1.3 (1-1.8) | 1.4 (1.2-2.2) |
| APTT | 34.7 (23.6-57) | 36.6 (28.2-57) | 34.8 (23.6-49.4) |
| TRAP test | 49.6 (12-156) | 53.3 (15-156) | 47.5 (12-113) |
| ASPI test | 36.8 (5-130) | 37.9 (10-130) | 36.5 (5-110) |
| ADP test | 31.6 (1-99.9) | 33.4 (13-99.9) | 31.2 (1-94) |
| RISTO low test | 10.9 (0-35) | 13.5 (4-25) | 10.2 (0-35) |
| RISTO high test | 56.5 (4-162) | 44.5 (7-115) | 60.1 (4-162) |
| D-dimer (mg/L) | 3568 (563-11026) | 3317 (595-10043) | 3637 (563-11026) |
| Protein C (%) | 56.5 (20.9-177.5) | 65.1 (41.4-105.1) | 61.6 (20.9-177.5) |
| Prothrombin (µg/mL) | 136.8 (36-422) | 149.2 (59.7-390) | 133.4 (36-422) |
| vWf (mU/mL) | 1941 (981-2372) | 1912 (986-2311) | 1890 (981-2372) |
| vWf activity (IU/mL) | 3.8 (1-7.7) | 4.2 (1.5-6.4) | 3.9 (1-7.7) |
| Omentin (ng/mL) | 1023 (579-2208) | 991 (731-1432) | 1028 (579-2208) |
| Vaspin (ng/mL) | 0.29 (0.1-0.84) | 0.43 (0.1-0.77) | 0.26 (0.1-0.84) |

1*P* value < 0.05 was considered statistically significant. The data are shown as the mean and range or percentage where applicable. PT: Prothrombin time; INR: International normalized ratio; vWf: von Willebrand factor; HCV: Hepatitis C virus.

**Table 7 Coagulation factors, platelet activity tests and adipokines levels with regards to the etiology of alcoholic liver cirrhosis**

|  | All patients  (*n =* 51) | Alcoholic  cirrhosis  (*n =* 30) | Non-alcoholic cirrhosis  (*n =* 21) |
| --- | --- | --- | --- |
| Thrombosis | 17/51 (33%) | 9/30 (30%) | 8/21 (38%) |
| PT (s) | 13.8 (11.3-44) | 17 (11.3-44) | 15.3 (11.3-21) |
| Prothrombin activity (%) | 67 (36-106) | 65.7 (36-106) | 68.8 (43-94) |
| INR | 1.3 (1-2.2) | 1.5 (1-2.2) | 1.4 (1.1-2) |
| APTT | 34.7 (23.6-57) | 34.6 (23.6-47.4) | 34.8 (28.2-57) |
| TRAP test | 49.6 (12-156) | 51.2 (16-113) | 47.2 (12-156) |
| ASPI test | 36.8 (5-130) | 39.1 (5-110) | 33.4 (5-130) |
| ADP test | 31.6 (1-99.9) | 32.8 (5-94) | 29.9 (1-99.9) |
| RISTO low test | 10.9 (0-35) | 11.4 (0-35) | 10.15 (1-25) |
| RISTO high test | 56.5 (4-162) | 68.4 (10-162) | 39.5 (4-115) |
| D-dimer (mg/L) | 3568 (563-11026) | 3635 (563-11026) | 3471 (595-10043) |
| Protein C (%) | 56.5 (20.9-177.5) | 59.2 (20.9-121.2) | 66.8 (33.4-177.5) |
| Prothrombin (µg/mL) | 136.8 (36-422) | **116.6 (36-382)** | **165.8 (59-422)\*** |
| vWf (mU/mL) | 1941 (981-2372) | 1937 (1209-2372) | 1834 (981-2311) |
| vWf (IU/mL) | 3.8 (1-7.7) | 4.1 (1.5-7.7) | 3.7 (1-6.4) |
| Omentin (ng/mL) | 1023 (579-2208) | 1072 (579-2208) | 923 (635-1432) |
| Vaspin (ng/mL) | 0.29 (0.1-0.84) | 0.29 (0.1-0.84) | 0.26 (0.1-0.72) |

1*P* value < 0.05 was considered statistically significant. The data are shown as the mean and range or percentage where applicable. PT: Prothrombin time; INR: International normalized ratio; vWf: von Willebrand factor.